SCHEMBL4901609

SCHEMBL4901609

CCOP(=O)(OCC)C(F)(F)c1ccc(Cn2c(-c3ccc(S(C)(=O)=O)cc3)cn(Cc3cccc(NC(C)=O)c3)c2=O)cc1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.37
MKNK2 Q9HBH9 2/20 0.37
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
FYN P06241 1/20 0.33
EPHX2 P34913 1/20 0.33
PTGS2 P35354 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
ACKR3 P25106 1/20 0.33
ESR1 P03372 1/20 0.33
ESRRG P62508 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LMNA P02545 2/20 0.33
SDHB P21912 1/20 0.32
SCN3A Q9NY46 1/20 0.32
TSHR P16473 1/20 0.32
ELANE P08246 1/20 0.32
MLNR O43193 1/20 0.32
MAPK8 P45983 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4901377 0.91 MKNK1 (0.37) MKNK1MKNK2MEN1KMT2AFYN
SCHEMBL4901617 0.88 MKNK1 (0.33) MKNK1MKNK2MEN1KMT2AFYN
SCHEMBL4900094 0.87 SDHB (0.34) MKNK1MKNK2PTGS2SDHB
SCHEMBL4901615 0.85 KMT2A (0.38) MEN1KMT2APTGS2GAAHPGD
SCHEMBL4899986 0.82 PTPN1 (0.34) PTGS2MAPK8MAPK9MAPK10
SCHEMBL4901282 0.82 PTGS2 (0.36) PTGS2MAPK8MAPK9MAPK10
SCHEMBL4903121 0.81 MAPK10 (0.40) MEN1KMT2AMAPK8MAPK10
SCHEMBL4903728 0.81 MAPK10 (0.40) MEN1KMT2AMAPK8MAPK10
SCHEMBL4890502 0.80 PTPN1 (0.41) PTGS2SDHBMAPK8MAPK9MAPK10
SCHEMBL4898600 0.79 PTPN1 (0.39) PTGS2ESR1ESRRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS MKNK1 150/4885MKNK2 138/4885MEN1 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.